All News

A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (wt based dose) W16: 41% ASAS40 v 23% PBO W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%) SAE 6%, discontinuation 3.5% #ACRBest https://t.co/ruW0ys49gk
Eric Dein  ( View Tweet)
Development of New classification crieteria to target patients earlier in thier #OA disease course! One tatget molecule will not solve this heterogeneous disease! @rheumnow #ACR23 https://t.co/waynA6RdUg
Bella Mehta bella_mehta ( View Tweet)
Intriguing data on #GCA treated with tocilizumab #aneurysm still occurs #vasculitis https://t.co/6cPlFRReLJ

Links:

KenWarringtonMD MdWarrington ( View Tweet)
A#2546 Anti-IFX Ab in AS #ACR23 @RheumNow Anti-IFX in 45% in f/u, 85% in 1st yr MTX decr anti-IFX (18 v 42%) Anti-IFX - higher inflamm markers, infus rxn, lower serum levels and Rx fail Pt w/o anti-IFX Ab more likely to tolerate tapering https://t.co/eN9SqGyGgm
Eric Dein  ( View Tweet)
Nepal et al. No increased risk of GI perforation for tocilizumab in GCA HR 1.05 . Diverticulitis (RR 3.51), IV methylprednisolone (RR 5.41) risk factors. This fits with my priors, steroids are a bigger risk than tocilizumab. Abstr#2560 #ACR23 @RheumNow https://t.co/BAmBQA0kEP https://t.co/zRjmDIkOHp
Richard Conway  ( View Tweet)
After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world https://t.co/yBBqYJZVOe
Janet Pope  ( View Tweet)
Great work @HoromanskiMd on a vasculitis in pregnancy plenary session! #ACR23 https://t.co/WSmqJjfBes

Links:

Mike Putman EBRheum ( View Tweet)
TM65 @ #ACR23 65 yo white M p/w 9mo of cryptogenic strokes. PMH: HTN, Crohn's - 07/2022: CRAO, BMRI: L frontal lobe infarct --> ASA, Atorvastatin started - 09/2022: weakness, vision changes --> BMRI: multifocal subacute infarcts --> Apixaban started, Vedolizumab started for… https://t.co/pjoCv7PH9Y https://t.co/YUN78nn6Xb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Synovial tissue histology correlates w/ several clinical parameters in early naive RA Combination ohigh CD68 infiltrate Fibrinoid Necrosis in tissue asso w/ -better DA reduction -higher EULAR moderate/good resp Included in a prediction model (AUC0.7) @RheumNow #ACR23 ABST2483 https://t.co/2jCMSzV7ak
Aurelie Najm  ( View Tweet)
Fantastic presentation by Desh Nepal from MCW on risk of GI perforation in patients with #GCA Low incidence , no association with TCZ, but increased risk with IV methylprednisolone and h/o diverticulitis. @EBRheum #ACR23 https://t.co/bgvmjAXBEY
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Kaymakci et al. 49 GCA patients in clinical remission undergoing thoracic aortic surgery. Active aortitis in 82%. Abstr#2557 #ACR23 @RheumNow https://t.co/WQh47LThGD https://t.co/DeORKmjYP7
Richard Conway  ( View Tweet)
#ACR23 Abs 2463 data from first 3 pts suggest CD19 CAR-T provides possible drug-free remission and resolution of lung/muscle inflammation in antisynthetase syndrome. https://t.co/7udqkDBgqT @rheumnow https://t.co/LSHcI0HMTM
Dr. Rachel Tate  ( View Tweet)
A#2547 #ACR23 @RheumNow Diff 2 Treat (D2T) AxSpa D2T: fail 2+ b/tsDMARDs w 2 MoA Very D2T: failure of Rx in less than 2 yrs 28% D2T, 3.8% Very D2T (Compare to 7-10% D2TRA) More likely: peripheral, uveitis, higher BASDAI, FM Very D2T also w IBD, higher CRP, longer dis duration https://t.co/HcIXnDRrIq
Eric Dein  ( View Tweet)
*not a cappuccino. The dregs of the coffee pot that the kind lady refused to charge me for. But jet lag is kicking in hard & so is desperation for any caffeine. If it wasn’t irAE friends @cappelliMD @jeffsparks et al up next, I would go to bed. #ACR23 must roll on! @RheumNow https://t.co/RdCOZlZMbZ
David Liew drdavidliew ( View Tweet)
Another infusion option for axSpA! INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA Efficacious - ASAS40 response sustained thru 52 weeks Safety profile similar to subq version @RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Robert B Chao, MD  ( View Tweet)
Pregnancies outcomes in vasculitis: - Higher frequency of spontaneous abortion and preterm delivery - 12% had pre-eclampsia - Risk higher in multiparous > nalliparous - Risk highest in small vessel vasculitis Rector A, Abst#2425 #ACR23 #ACRBest @RheumNow https://t.co/TgbRWw9il5

Dr. Antoni Chan  ( View Tweet)

Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators #ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33
Janet Pope  ( View Tweet)
Body mass is associated w/ ttmt response in RA Data from RACAT & TEAR studies TNFi > triple th in underweight gpe but not in overweight gpe Similar result in gpe w/ low leptin levels & low adipokine scores True biology or confounding bias? @RheumNow #ACR23 ABST2541 https://t.co/OhKj6QNaSa
Aurelie Najm  ( View Tweet)
Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better response to TNFi, overweight/obese respond equally to both. Abstr#2541 #ACR23 @RheumNow https://t.co/SROD3esMCD https://t.co/ni3I8tD7wI
Richard Conway  ( View Tweet)
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux? Antibody titres better when not getting regular ritux around boosters Maybe boosters 9mo (or so) gap after ritux helps immunogenicity @TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
David Liew drdavidliew ( View Tweet)
×